INFO & CONTACTS:  +39 02 2390 1

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Procopio Giuseppe

Main Facility: Oncologia Medica Genitourinaria

Drug: Ifinatamab Deruxtecan (I-Dxd)(MK2400) 12mg/kg vs Docetaxel 75 mg/mq

Pathologies: Prostate tumors

Each participant will participate in the study for approximately 2 years from the time the participant provides documented informed consent through the final protocol-specified contact. After a screening period of up to 42 days, each participant will be receiving assigned study intervention until disease progression is radiographically documented, verified by BICR per PCWG Modified RECIST 1.1, unacceptable AEs, intercurrent illness that prevents further administration of study intervention, investigator’s decision to discontinue the participant, withdrawal of consent, or administrative reasons requiring cessation of treatment. After EOT each participant will be followed for the occurrence of adverse events as described in Section 8.4. After screening, each participant will be assigned to receive study intervention until one of the conditions for discontinuation of study intervention is met. Participants assigned to receive docetaxel will receive study intervention for up to 10 cycles. Participants who discontinue for reasons other than BICR-verified radiographic disease progression will have post treatment follow-up imaging for disease status until any of the conditions for discontinuation of imaging are met. After the end of treatment, each participant will be followed for the occurrence of AEs, SAEs, and other reportable safety events. In addition, all participants will be followed for overall survival until death, withdrawal of consent, the end of the study, or enrollment into an extension study. 

Last update: 20/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe